Received May 26, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
dermatomal rash/ The rash itches; This non-serious case was reported by a consumer and described the occurrence of itchy rash in a 44-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included atazanavir sulfate;cobicistat (Evotaz). On 13-MAY-2026, the patient received Shingrix .5 ml. On 16-MAY-2026, 3 days after receiving Shingrix, the patient experienced itchy rash (Verbatim: dermatomal rash/ The rash itches). The outcome of the itchy rash was not resolved. It was unknown if the reporter considered the itchy rash to be related to Shingrix. It was unknown if the company considered the itchy rash to be related to Shingrix. Additional Information: GSK Receipt Date:19-MAY-2026 The batch number was not provided upon follow up with the reporter.
EVOTAZ